Published

Safety and tolerability of inhaled N,N-Dimethyltryptamine (BMND01 candidate): A phase I clinical trial.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology
Date: 2024-03-01
Source: PubMed
DOI: 10.1016/j.euroneuro.2023.12.006
PubMed: 38141403

Authors

Falchi-Carvalho M Wießner I Silva SRB O Maia L Barros H Laborde S Arichelle F Tullman S Silva-Costa N Assunção A Almeida R Pantrigo ÉJ Bolcont R Costa-Macedo JV Arcoverde E Galvão-Coelho N Araujo DB Palhano-Fontes F

Watch author

Derived topics and classifications

psilocybin Pharmacology Receptor Pharmacology Clinical Trial Safety Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

From Trials to Clinics: Considerations for Implementing Psychedelic-Assisted Therapy Into Clinical PracticePharmacology Research & Perspectives · 2026-05-10 Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelicsFrontiers in Psychiatry · 2024-11-06 Psychedelics and Psychotherapy: Is the Whole Greater than the Sum of its Parts?Clinical Pharmacology & Therapeutics · 2023-10-05 Overcoming Pharmacokinetic and Peripheral Safety Challenges in Psychedelic Therapies: The Promise of Advanced Drug Delivery Systems.ACS pharmacology & translational science · 2026-06-12 Acute Analgesic Effects of DMT on Experimentally Induced Acute Nociceptive Pain, Hyperalgesia and Allodynia in Healthy ParticipantsClinicalTrials.gov · 2026-04-02 Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in a Randomized, Placebo-controlled, Cross-over Trial in Healthy Participants (LPD-Study)ClinicalTrials.gov · 2025-03-27 Psychedelic Therapy: A Primer for Primary Care Clinicians-Psilocybin.American journal of therapeutics · 2024-01-01 Mindfulness and Psychedelics: A Combined Neurophenomenological and Pharmacological Approach to the Characterization of Mindfulness States in Experienced MeditatorsClinicalTrials.gov · 2023-09-21